APA (7th ed.) Citation

DB, W., KA, C., SS, B., JL, O., E, S., BA, M., . . . LS, C. (2021). Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. Laryngoscope investigative otolaryngology, 6(5), 1008. https://doi.org/10.1002/lio2.643

Chicago Style (17th ed.) Citation

DB, Welling, et al. "Early Phase Clinical Studies of AR-42, a Histone Deacetylase Inhibitor, for Neurofibromatosis Type 2-associated Vestibular Schwannomas and Meningiomas." Laryngoscope Investigative Otolaryngology 6, no. 5 (2021): 1008. https://doi.org/10.1002/lio2.643.

MLA (9th ed.) Citation

DB, Welling, et al. "Early Phase Clinical Studies of AR-42, a Histone Deacetylase Inhibitor, for Neurofibromatosis Type 2-associated Vestibular Schwannomas and Meningiomas." Laryngoscope Investigative Otolaryngology, vol. 6, no. 5, 2021, p. 1008, https://doi.org/10.1002/lio2.643.